The purpose of this CME activity is to educate practicing physicians and other healthcare professionals about the most recent clinical trials and case series in the field of metabolic psychiatry. This emerging evidence suggests that nutritional ketosis may be a powerful tool as an adjunct to standard medical management of severe mental illness (e.g. bipolar, schizophrenia, depression). By demonstrating that the body of evidence in this field is increasing, we hope to persuade clinicians to consider this type of dietary therapy as an option in the care of their patients.
Target Audience
The main target audiences are primary care and psychiatry physicians, nurse practitioners, and physician assistants. Also, of important consideration are licensed mental health therapists and dieticians.
Learning Objectives
After completing this activity, the participant should be better able to:
-
Explain the purported mechanisms for a connection between metabolic and mental health.
-
Describe why metformin can also improve the symptoms of bipolar depression by improving insulin resistance.
-
Describe the findings of a paper showing that inpatient initiation of a ketogenic diet improved psychiatric symptoms and medication usage for patients with bipolar disorder, major depression, and schizophrenia.
-
Describe the findings of a study showing that outpatient use of ketogenic diets improved metabolic health and psychiatric symptoms in patients with bipolar disorder and schizophrenia.
-
Incorporate acquired knowledge on the latest findings on ketogenic therapy for serious mental illness into current practice to better address the needs of their patients, and to optimize patient outcomes.
 |
Matthew Bernstein, MD
|
 |
Bret Scher, MD |
European Accreditation Council for Continuing Medical Education (EACCME)
EACCME Accreditation Statement
The Evidence Supporting Ketogenic Therapy for the Treatment of Serious Mental Illness, made available on https://www.medtalks.com/ketogenic-therapy-treatment-of-serious-mental-illness and organized by Dane Garvin Ltd., is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists.
Only those e-learning materials that are displayed on the UEMS-EACCME® website have formally been accredited.
EACCME Term Offering
July 22, 2025 to July 22, 2027
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.
Information regarding the conversion of EACCME® credits
Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at https://edhub.ama-assn.org/pages/applications to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.
For other countries, please contact the relevant national/regional accreditation authority.
American Academy of Family Physicians (AAFP) Accreditation
AAFP Accreditation Statement
The AAFP has reviewed The Evidence Supporting Ketogenic Therapy for the Treatment of Serious Mental Illness and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 03/18/2025 to 03/18/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Grant
This activity is supported by an educational grant from Metabolic Mind which is a non-profit organization.
References
The Evidence Supporting Ketogenic Therapy for the Treatment of Serious Mental Illness
